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Abstract
Background: NC1 domains from a1, a2, a3 and a6(IV) collagen chains were shown to exert anti-tumor or anti-angiogenic
activities, whereas the NC1 domain of the a4(IV) chain did not show such activities so far.
Methodology/Principal Findings: We demonstrate in the present paper that the NC1 a4(IV) domain exerts a potent anti-
tumor activity both in vitro and in an experimental human melanoma model in vivo. The overexpression of NC1 a4(IV) in
human UACC-903 melanoma cells strongly inhibited their in vitro proliferative (–38%) and invasive (–52%) properties. MT1-
MMP activation was largely decreased and its cellular distribution was modified, resulting in a loss of expression at the
migration front associated with a loss of migratory phenotype. In an in vivo xenograft model in athymic nude mice, the
subcutaneous injection of NC1 a4(IV)-overexpressing melanoma cells induced significantly smaller tumors (–80% tumor
volume) than the Mock cells, due to a strong inhibition of tumor growth. Exogenously added recombinant human NC1
a4(IV) reproduced the inhibitory effects of NC1 a4(IV) overexpression in UACC-903 cells but not in dermal fibroblasts. An
anti-avb3 integrin blocking antibody inhibited cell adhesion on recombinant human NC1 a4(IV) substratum. The
involvement of avb3 integrin in mediating NC1 a4(IV) effect was confirmed by surface plasmon resonance (SPR) binding
assays showing that recombinant human NC1 a4(IV) binds to avb3 integrin (KD=14869.54 nM).
Conclusion/Significance: Collectively, our results demonstrate that the NC1 a4(IV) domain, named tetrastatin, is a new
endogenous anti-tumor matrikine.
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Introduction
Tumor invasion and metastasis require proteolytic degradation
of extracellular matrix (ECM). This degradation involves various
proteolytic cascades, such as matrix metalloproteinase (MMP)
activation and the plasminogen activation system. MMPs belong
to a zinc-dependent proteinase family with 23 members, secreted
as inactive zymogens. MT-MMPs represent an MMP subfamily
containing an additional transmembrane or anchor domain which
links the enzyme to the plasma membrane. MT-MMPs, especially
MT1-MMP, actively participate in the basement membrane
degradation either directly or by activating latent pro-MMP-2
and pro-MMP-13 [1–3]. It is concentrated at the leading edge of
migrating cells and interacts with caveolin-1, a caveolae compo-
nent involved in endocytosis and MT1-MMP recycling to the
plasma membrane [4,5].
The extracellular matrix (ECM) is a complex structure
composed of many different proteins, proteoglycans and
hyaluronic acid. All basement membranes, specialized forms of
extracellular matrix, comprise type IV collagen, laminins,
nidogens and perlecan [6]. Six different type IV collagen
a chains (a1(IV)-a6(IV)) have been identified [7]. They are
composed of a 7S domain within the N-terminal domain, an
interrupted triple helical domain and a globular C-terminal
non-collagenous (NC1) domain [8]. The a-chains twist around
one another to form a triple helix. Type IV collagen molecules
associate via their 7S domain, their NC1 domain and laterally
to form a three-dimensional network. Although the a1 and a2
chains are widely expressed and colocalize in numerous tissues,
there is a temporal and spatial regulation of a3, a4, a5 and a6
expression in physiological and pathological processes.
Tumor progression and neoangiogenesis depend on a control
exerted by tumor microenvironment including several intact ECM
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kines [9]. Among them, the NC1 domains of several a(IV) collagen
chains have been shown to inhibit angiogenesis and tumor growth
[10–14] via integrin binding [15–20].
The NC1 a4(IV) domain was shown to lack anti-angiogenic or
anti-tumor properties in a chick embryo model [10,15]. We
demonstrate here that the NC1 a4(IV) domain exerts a potent
anti-tumor activity both in vitro and in an in vivo experimental
human melanoma model, by decreasing proliferative and invasive
properties of melanoma cells. We also provide evidence that the
avb3 integrin could mediate the biological effects of the NC1
a4(IV) domain.
Materials and Methods
Ethics Statement
All animal experiments were performed in level 2 animal
facilities of the Faculty of Medicine and Pharmacy of Reims, in
accordance with the CNRS institutional guidelines (http://
ethique.ipbs.fr/) and in conformity with the French Ministry of
Research and Agriculture Charter on Animal Experimentation
Ethics. Procedure of animal study was approved by the Ethics
Committee of the Federative Research Institute (IFR53) from
Reims Champagne-Ardenne University.
Collection and utilization of human skin biopsies were approved
by the Institutional Review Board of the Reims University
Hospital (CHU de Reims) and a written informed consent was
required from patients.
Reagents
Culture reagents, molecular biology products, G418 also named
Geneticin (a gentamicin analog), Lipofectamine 2000 Reagent
came from Invitrogen (distributed by Fischer Scientific, Illkirch,
France). Bovine serum albumin, gelatin, MatrigelH (ECM gel),
p3xFLAG-CMV-9 vector and anti-FLAG-M2 antibody were
purchased from Sigma (St-Quentin Fallavier, France). pQE-31
vector and Ni-NTA resin were from Qiagen (Courtaboeuf,
France). Goat anti-mouse MT1-MMP, anti-avb3 integrin anti-
body (23C6) were from Santa-Cruz (distributed by Tebu, Le
Perray-en-Yvelines, France). The His tag monoclonal antibody
was from Genscript (Piscataway, USA). Rabbit anti-human NC1
a4(IV) was produced by Covalab (Oullins, France). Ki-67 rabbit
polyclonal antibody (clone EPR3610) was from Epitomics
(distributed by Euromedex, Mundolsheim, France). The Alexa
Fluor 488 goat anti-rabbit antibody was from Invitrogen
(distributed by Fischer Scientific, Illkirch, France). Mayer’s
Hemalun was from Merck (Fontenay-sous-bois, France). The
anti-caveolin polyclonal antibody was from Cell signaling
(distributed by Ozyme, Saint Quentin en Yvelines, France).
Cell Culture
UACC-903 human melanoma cells were originally obtained
from Dr J.M. Trent, University of Arizona Cancer Center [21].
HT-144 (HTB-63
TM) and SK-MEL-28 human (HTB-72
TM)
melanoma cells were from ATCC. They were cultured in DMEM
with 4.5 g/L glucose and 10% FBS at 37uC in a humid
atmosphere (5% CO2, 95% air). Human dermal fibroblasts were
isolated from skin biopsies of human donors and cultured in
DMEM with 1 g/L glucose and 10% FBS at 37uC in a humid
atmosphere (5% CO2, 95% air). In all experiments, cell viability
was greater than 98%, as assessed by trypan blue exclusion.
Cloning of the NC1 a4(IV) Domains in the p3xFLAG
Expression Vector
p3xFLAG-NC1a4(IV)1-229]: The sequence encoding the com-
plete human NC1 a4(IV) domain (NC1[a4(IV)1-229]) was
amplified by reverse transcription-polymerase chain reaction from
kidney mRNA using the following sets of primers: 59-
TTTGGCCCTGGATACCTCGGT-39 and 59-CGCATTCTC-
TAGCTATACTTC-39. The resulting cDNA fragments were
cloned into a p3xFLAG-CMV-9 vector. The orientation and the
complete sequence of the insert were checked by sequencing. The
p3xFLAG-CMV-9 expression vector contains a human cytomeg-
alovirus promoter regulatory region that drives a high level
expression while the hGH polyadenylation signal enhances
mRNA longevity.
p3xFLAG-NC1[a4(IV)180-229]: The same experimental pro-
cedure was followed to clone the C-terminal part of the human
NC1 a4(IV) domain. The sequence encoding the human
NC1[a4(IV)180-229] region was amplified using the following
sets of primers: 59-CAGGGAACTTGCCACTTT-39 and 59-
CGCATTCTCTAGCTATACTTC-39.
Transfection of UACC-903 Cells
The human UACC-903 melanoma cells were transfected with
p3xFLAG-CMV-9, p3xFLAG-NC1[a4(IV)1-229] or p3xFLAG-
NC1[a4(IV)180-229] using Lipofectamine 2000 Reagent and
selected with 700 mg/mL G418. Clonal cell lines were screened by
RT-PCR using fusion protein specific primers: Forward 59-
CAAAGACCATGACGGTGATTAT-39 and Reverse 59-
TTCCAGGGCCAGGAGAGGCACT-39 and GAPDH specific
primers: Forward 59-ACCACAGTCCATGCCATCA-39 and Re-
verse: 59-TCCACCACCCTGTTGCTGT-39.
Immunodetection of the FLAG-NC1[a4(IV)] Fusion
Protein
To detect FLAG-NC1[a4(IV)] fusion protein by Western blot,
cell supernatants were collected and proteins were precipitated
with 12% trichloroacetic acid (TCA) and 0.1% Triton X-100.
Proteins (1.5 mg) were separated by SDS-PAGE and transferred to
an Immobilon-P
TM membrane. After blocking with 5% non-fat
dry milk in TBS buffer (50 mM Tris, 138 mM NaCl, 2.7 mM
KCl, pH 8.0), the membrane was incubated with an anti-FLAG-
M2 antibody (10 mg/mL in TBS with 3% non-fat dry milk)
overnight at 4uC. Then, the membrane was washed in TBS buffer
and incubated with a rabbit anti-mouse IgG, peroxidase-
conjugated (1/10000) for 1h30. Signals were detected using an
ECL+ kit (GE Healthcare, Orsay, France), according to the
manufacturer’s instructions.
In vitro Proliferation Assays
Cell proliferation was evaluated using the WST-1 reagent
according to the manufacturer’s instructions (Roche Diagnostic,
Meylan, France). 2610
4 cells were seeded onto 96-well plates and
incubated for 24, 48, 72 hours in 1 mL DMEM containing 2%
FBS. 50 mL of WST-1 were added to the medium and, after
a 20 min incubation period, absorbance was measured at 450 nm.
Cell numbers were also assessed by the crystal violet assay. After
the incubation periods, cells were fixed for 15 min with 1.1%
glutaraldehyde, then stained for 15 min with a 0.1% crystal violet
solution. Absorbance was measured at 560 nm.
In vitro Invasion Assays
Invasion was assayed in modified Boyden chambers (tissue
culture treated, 6.5 mm diameter, 8 mm pore, Greiner-One,
Tetrastatin: A Novel Anti-Tumor Matrikine
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4 cells were suspended in serum-free
DMEM with 4.5 g/L glucose containing 0.2% BSA and seeded
onto membranes coated with MatrigelH (30 mg/cm
2). The lower
compartment was filled with DMEM supplemented with 10% FBS
and 2% BSA. After a 72 h incubation period, cells were fixed with
methanol and stained with crystal violet for 15 min. Cells
remaining on the upper face of the membrane were scraped.
Crystal violet staining of the migrated cells was eluted in 10%
acetic acid and absorbance was read at 560 nm. The total amount
of cells was also evaluated (without scraping) in each condition.
The absorbance resulting from the migrating cell was reported to
the absorbance of all the cells to determine the percentage of
migration.
Adhesion Assays
Cells were detached with 50 mM Hepes, 125 mM NaCl, 5 mM
KCl and 1 mM EDTA, washed three times with DMEM,
preincubated for 30 min with different effectors and 3610
4 cells
were seeded per well of 96 well-plate previously coated with
recombinant NC1 a4(IV) and saturated with 1% BSA. After 30,
60 or 90 min of adhesion, cells were washed three times with PBS,
fixed with 1.1% glutaraldehyde and stained with crystal violet.
After elution with 10% acetic acid, absorbance was read at
560 nm.
In vivo Tumor Growth Measurement
Female athymic nude mice (6 week-old; average body weight:
18–20 g) were purchased from Harlan France (Gannat, France).
Animals were individually caged and given food and water ad
libitum. They were kept in a room with constant temperature and
humidity. All mice were acclimatized to laboratory conditions for
1 week before starting the experiments. A suspension of Mock or
NC1 a4(IV) overexpressing-UACC-903 cells (5610
6 cells in
0.15 mL DMEM with 4.5 g/L glucose) was subcutaneously
injected into the left side of mice. Tumor size was measured at
days 10, 14, 19 and 26. Mice were sacrificed at day 26 and tumor
sizes measured. Each group contained at least 10 mice. Tumor
volumes were determined according to v=K A6B
2, where A
denotes the largest dimension of the tumor and B represents the
smallest dimension [22]. Tumors were frozen in isopentane and
Figure 1. Selection of NC1 a4(IV) overexpressing cell clones. UACC-903 cells were transfected with either p3xFLAG-CMV-9 (Mock 1, 2, 3) or
p3xFLAG-NC1[a4(IV)] (NC1 a4(IV) 1, 2, 3). (A): RT-PCR: Total RNA was isolated from clones selected for G418 resistance and analyzed by RT-PCR using
p3xFLAG-CMV-9 (1) and GAPDH specific primers (2). (B): Western-blot: Three clones were selected by RT-PCR for their high gene expression of FLAG
epitope and FLAG-NC1[a4(IV)] fusion protein. Supernatant from Mock cells and from cells stably transfected with FLAG-NC1[a4(IV)] were tested for
the 28 kDa fusion protein secretion by Western blot using an anti-FLAG monoclonal antibody or an anti-NC1 a4(IV) polyclonal antibody.
doi:10.1371/journal.pone.0029587.g001
Tetrastatin: A Novel Anti-Tumor Matrikine
PLoS ONE | www.plosone.org 3 April 2012 | Volume 7 | Issue 4 | e29587kept at 280uC until use. 5 mm thick sections of OCT-embedded
samples were fixed with 4% fresh paraformaldehyde in phosphate
buffered saline (PBS), pH 7.2 at room temperature for 15 min.
The slides were washed with PBS and saturated in PBS with 2%
BSA, 0.1% triton X-100 in PBS for 30 min and incubated with an
anti-Ki-67 rabbit monoclonal antibody (dilution: 1/100) at 4uC
overnight. After washing with PBS, the slides were treated for
30 min at room temperature with the Alexa Fluor 488 goat anti-
rabbit antibody (dilution: 1/200). Counterstaining was performed
with Mayer’s Hemalun. Quantification was assessed using ImageJ
software.
Western Blot Analysis
Samples were electrophoresed in a 0.1% SDS, 10% poly-
acrylamide gel. They were then transferred onto Immobilon-P
membranes (Millipore, St Quentin en Yvelines, France). The
membranes were blocked with 5% non-fat dry milk, 0.1% Tween
20 in TBS for 2 h at room temperature, incubated overnight at
4uC with anti-MT1-MMP antibody (0.2 mg/mL), and then for 1 h
at room temperature with a second peroxidase-conjugated anti-
IgG antibody. Immune complexes were visualized with the ECL
chemiluminescence detection kit (GE Healthcare, Orsay, France).
Immunofluorescence
Cells were plated on glass-slides and incubated overnight at
37uC and then fixed with 4% (v/v) paraformaldehyde for 5–
10 min at 4uC. The slides were washed with PBS and saturated in
PBS with 3% BSA for 30 min. Cells were then incubated
overnight at 4uC with anti MT1-MMP antibody and/or with
anti-caveolin-1 antibody. Slides were washed five times in PBS and
cells were incubated for 1h with Alexa Fluor 488-conjugated
secondary antibody to detect anti-MT1-MMP antibody and Alexa
Fluor 568-conjugated secondary antibody to detect anti-caveolin-
1. Both secondary antibodies were diluted 1/1000 in PBS with 3%
BSA.
Cells were then washed with PBS. Control preparations were
incubated without the first antibody. Nuclei were counterstained
with DAPI. Immunofluorescence-labeled cell preparations were
analysed using a Zeiss LSM 710 confocal laser scanning
microscope with the 63X oil-immersion objective zoom 3X and
Zeiss operating system (Carl Zeiss MicroImaging GmbH,
Germany). Acquisitions were performed by exciting the Alexa
Fluor 488, the Alexa Fluor 568 and the DAPI dye with the Argon
laser, HeNe laser and chameleon IR laser tuned at 730 nm
respectively. Emitted fluorescence was detected through the
appropriate wavelength window. Thirty images were captured
Figure 2. NC1 a4(IV) overexpression inhibits in vitro melanoma cell proliferation. (A): Cell proliferation was measured using WST-1 reagent
after 24, 48 and 72 h as described in Materials and Methods (mean of three clones6SD. ***: p,0.001) (A). (B): Cell proliferation of the three selected
clones at T 72 h.
doi:10.1371/journal.pone.0029587.g002
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softwares.
Expression and Purification of Recombinant Human NC1
a4(IV) Domain
The sequence encoding the complete human NC1 a4(IV)
domain (NC1[a4(IV)1-229]) was obtained as described in the
‘‘Cloning of the NC1 a4(IV) domains in the p3xFLAG expression
vector’’ section.
The resulting cDNA fragments were cloned into a pQE-31
vector (Qiagen, Courtaboeuf, France). The orientation and the
complete sequence of the insert were checked by sequencing.
Recombinant human NC1 a4(IV) domain was expressed in
Escherichia coli JM109, DE3 strain (Promega, Charbonnie `re-les-
bains, France). Transformed cells were grown at 37uC in 100 mL
of Luria Bertani medium containing 50 mg/mL of ampicillin until
the A600nm was about 0.6. Protein expression was induced by
addition of 0.4 mM isopropyl-ß-D-thiogalactopyranoside (IPTG).
After 4 h culture at 37uC under agitation, bacterial suspension was
harvested by centrifugation at 4000 g for 15 min at 4uC. The
pellets were resuspended in 5 mL of 50 mM NaH2PO4, 300 mM
NaCl, 10 mM imidazole, pH 8. The cells were disrupted by thaw/
freeze cycle and sonication. After centrifugation at 10 000 g for
30 min, supernatant (4 mL) was incubated for 1 h with 1 mL of
Ni-NTA superflow resin. The resin was then poured into
a chromatography column, washed with 4 mL of 50 mM
NaH2PO4, 300 mM NaCl, 20 mM imidazole, pH 8. Finally, the
recombinant domain was eluted with 360.5 mL of elution buffer
(50 mM NaH2PO4, 300 mM NaCl, 250 mM imidazole, pH 8).
After dialysis against distilled water, its purity was assessed by
SDS-PAGE and by Western blotting using an anti-NC1 a4(IV)
polyclonal antibody or an anti-6 His monoclonal antibody.
Surface Plasmon Resonance Binding Assays
The surface plasmon resonance (SPR) measurements were
performed on a BIAcore T100 instrument (GE Healthcare,
Uppsala, Sweden, Technichal facility, IFR 128, Lyon, France).
Full-length avb3 integrin (Millipore, Saint Quentin en Yvelines,
France) was immobilized via its primary amine groups onto a CM5
sensor chip as previously described [23]. The immobilization level
ranged from 1341 to 2655 Resonance Units (RU). Binding assays
were performed at 25uC in 10 mM Hepes buffer, pH 7.4,
containing 150 mM NaCl, 1 mM MgCl2, 2 mM MnCl2, and
50 mM b-octyl-D-glucopyranoside as running buffer. Recombi-
nant human NC1 a4(IV) was injected at several concentrations
and different flow rates over immobilized avb3 integrin. The
surface was then regenerated with a pulse (60 s) of 10 mM EDTA.
The kinetic parameters ka and kd (association and dissociation rate
constants, respectively) were analyzed simultaneously usinga global
data analysis program (Biacore T100 evaluation software version
2.0.3) that fitted simultaneously the sensorgrams obtained at
different concentrations of NC1 a4(IV), constraining the kinetic
rate constants to a single value for each set of curves. Rmax, the
maximal capacity of the surface was floated during the fitting
procedure.
Statistical Analyses
All the in vitro experiments were done in triplicate and data
represent the mean of two different experiments. Statistical
analyses were performed by Student’s t test. Results were
expressed as mean6SD. For in vivo experiments, volumes of
primary tumors were statistically analyzed using the non para-
metric u-test of Mann and Withney.
Figure 3. NC1 a4(IV) overexpression inhibits in vitro melanoma cell invasion. Mock or NC1 a4(IV) clones were tested for their ability to
migrate through MatrigelH-coated membranes as described in Materials and Methods. (A) Representative photomicrograph shows Mock or NC1
a4(IV)-overexpressing cell invasion after a 72 h incubation period. Scale bar: 10 mm. (B) Representative bar graph quantifying Mock or NC1 a4(IV)-
overexpressing cell invasion. ***: p,0.001.
doi:10.1371/journal.pone.0029587.g003
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3xFLAG-NC1[a4(IV)1-229] Fusion Protein Production in
Stably Transfected UACC-903 Cells
To assess the role of the NC1 a4(IV) domain in melanoma
progression, UACC-903 cells were transfected with either the
control p3xFLAG-CMV-9 or the p3xFLAG-NC1[a4(IV)1-229].
All the vectors contained the aminoglycoside phosphotransferase
II gene, which confers resistance to aminoglycosides such as
Geneticin (G418), allowing the selection of stable transfectants.
They also encode three adjacent FLAG epitopes upstream of the
multiple cloning region in which we inserted NC1[a4(IV)1-229]
cDNA. This resulted in an increased detection sensitivity of the
secreted FLAG-NC1[a4(IV)1-229] fusion protein. Clones selected
with G418 were screened by RT-PCR for their expression of
FLAG epitope (amplicon size: 195 bp) or FLAG-NC1[a4(IV)1-
229] fusion protein (amplicon size: 882 bp) expression compara-
tively to GAPDH expression. Three clones with high FLAG
mRNA expression and three clones with high FLAG-
NC1[a4(IV)1-229] mRNA expression, named Mock 1, 2, 3 and
NC1 a4(IV) 1, 2, 3 respectively (Figure 1A), were selected for the
experiments. FLAG epitope and FLAG-NC1[a4(IV)1-232] fusion
Figure 4. NC1 a4(IV) overexpression decreases MT1-MMP activation and modifies MT1-MMP distribution. (A): Mock or NC1 a4(IV)-
overexpressing cells were incubated for 48 h without FBS. MT1-MMP expression and activation in whole cell extracts were analyzed by Western blot
with an antibody directed against the hinge region of MT1-MMP. The membrane was dehybridized and reprobed with an anti-actin antibody.
Quantifications were performed by densitometry using the Bio-1D software. Results were expressed as arbitrary units (AU). NS: Non significant. ***:
p,0.001. (B): Cells were cultured on glass slides, fixed with paraformaldehyde and labelled with an anti-MT1-MMP directed against both the pro and
the active form (green), anti-caveolin 1 (red). Yellow staining corresponds to areas where proMT1-MMP and caveolin-1 colocalized and white arrows
in the insert underline the colocalization at the migration front at a higher magnification. Nuclei were conterstained with DAPI (blue). Scale bar: 5 mm.
doi:10.1371/journal.pone.0029587.g004
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Mock and NC1[a4(IV)] transfected cells respectively using an anti-
FLAG antibody (data not shown). Moreover, the fusion protein
(Mw: 28 kDa) was detected in the NC1 a4(IV) transfected cell
supernatants by Western blot using the same anti-FLAG antibody
and an anti-NC1 a4(IV) polyclonal antibody, confirming that the
fusion protein was indeed secreted into the extracellular
compartment (Figure 1B).
In vitro Melanoma Cell Proliferation is Decreased by NC1
a4(IV) Overexpression
In order to measure in vitro clone proliferation, cells were seeded
onto 96-well plates with 2% FBS and proliferation was measured
using the WST-1 reagent after 24 h, 48 h and 72 h of incubation
(Figure 2A). Figure 2B shows the data obtained with the different
clones tested after 72 h. Overexpression of NC1 a4(IV) inhibited
cell proliferation by 20%, 28% and 38% (p,0.001) after 24 h,
48 h, and 72 h respectively, but did not induce UACC-903 cell
apoptosis in the different clones, as evaluated by Hoechst 33342
staining (Figure S1). The C-terminal NC1[a4(IV)180-229] domain
also induced a strong decrease (–42%, p,0.001) in cell pro-
liferation after 72 h (Figure 2).
In vitro Melanoma Cell MatrigelH Invasion is Decreased
by NC1 a4(IV) Overexpression
NC1 a4(IV)-overexpressing UACC-903 melanoma cells were
tested for their ability to migrate through MatrigelH-coated
(30 mg/cm
2) filters for 72 h (Figure 3). The overexpression of
Figure 5. NC1 a4(IV) overexpression by melanoma cells decreases tumor growth in a mouse xenograft model. Mock or NC1 a4(IV)-
overexpressing UACC-903 cells (5610
6 cells) were subcutaneously injected into the left side of athymic mice. (A): Tumor size was measured at days
10, 14, 19 and 26. Tumor volumes were determined according to v=K A6B
2, where A denotes the largest dimension of the tumor and B represents
the smallest dimension, and expressed as mean6SD (n=10). ***: p,0.001. The insert shows example of tumors obtained in each mouse series after
injection of Mock or NC1 a4(IV)-overexpressing cells. (B): Immunostaining of tumor section with an anti-Ki67 antibody. Quantification was performed
with Image J. Scale bar: 50 mm.
doi:10.1371/journal.pone.0029587.g005
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comparatively to Mock tranfected cell clones. The C-terminal
NC1[a4(IV)180-229] domain also induced a strong decrease (–
77%, p,0.001) in cell invasion (Figure 3).
The plasminogen-plasmin activation system and matrix metal-
loproteinase activation are two major proteolytic cascades involved
in melanoma progression [24,25]. The overexpression of NC1
a4(IV) did not induce any significant change in the plasminogen
activation system (Figure S2 A).
Matrix metalloproteinases, especially MMP-2, MMP-9 and
MT1-MMP (also named MMP-14), are largely involved in
extracellular matrix degradation and melanoma cell migration
[25,26]. ProMMP-9 was not detected in the conditioned media of
NC1 a4(IV)-overexpressing cells and no significant change in
proMMP-2 secretion was detected by gelatin-zymography analysis
in the supernatant of NC1a4(IV)-overexpressing cells compared to
Mock cells (Figure S2 B). Likewise, reverse zymography analysis of
Tissue Inhibitors of Matrix Metalloproteinases (TIMPs) in
conditioned media did not show any significant change in
TIMP-2 secretion (Figure S2 C).
Figure 6. Recombinant human NC1 a4(IV) inhibits in vitro melanoma cell proliferation and invasion. (A): Recombinant human NC1 a4(IV)
domain obtention: Recombinant human NC1 a4(IV) domain was expressed in E. coli JM109, DE3 strain (1) SDS-PAGE (lane M: low molecular weight
markers; lane 1: T4h crude lysate, non-induced by IPTG; lane 2: T4h crude lysate, induced by IPTG, lane 3: recombinant human NC1 a4(IV) domain
purified by chromatography on a Ni-NTA superflow resin. (2) Western blot using an anti-NC1 a4(IV) antibody. Lane 1, 2, 3: same as above. (3) Western
blot using an anti-His tag antibody. Lane 1, 2, 3: same as above. (B): Cell proliferation: Melanoma cells and dermal fibroblasts were incubated without
or with 10 or 20 mg/mL recombinant human NC1 a4(IV) for 48 h. Cell proliferation was measured as described in the Material and Methods section.
NS: Non significant. ***: p,0.001. (C): Cell invasion: UACC-903 melanoma cells were incubated without or with 20 mg/mL recombinant human NC1
a4(IV). Cell invasion was measured as described in the Material and Methods section. ***: p,0.001.
doi:10.1371/journal.pone.0029587.g006
Tetrastatin: A Novel Anti-Tumor Matrikine
PLoS ONE | www.plosone.org 8 April 2012 | Volume 7 | Issue 4 | e29587NC1 a4(IV) Overexpression Inhibits MT1-MMP Activation
A crucial role of MT1-MMP has been demonstrated in cell
invasion [1,2]. NC1 a4(IV) overexpression did not modify
proMT1-MMP mRNA expression measured by real time PCR
analysis (data not shown). As demonstrated by Western blot using
a rabbit anti-MT1-MMP polyclonal antibody that recognized
both pro and active MT1-MMP, the total amount of MT1-MMP
protein was not significantly altered. However, NC1 a4(IV)
overexpression decreased proMT1-MMP activation by 72% as
shown by measuring the active MT1-MMP/total MT1-MMP
ratio (Figure 4A). Since active MT1-MMP is able to degrade
extracellular matrix, the decrease in MT1-MMP activation could
contribute to the inhibition of MatrigelH invasion observed with
NC1 a4(IV)-overexpressing cells. Immunolocalization using the
same anti-MT1-MMP antibody showed that in Mock cells, MT1-
MMP was localized in the cytoplasm and at the migration front
(Figure 4B). In contrast MT1-MMP was strongly decreased at the
migration front in NC1 a4(IV)-overexpressing cells where it
accumulated in the cytoplasm. As caveolin-1 was shown to directly
interact with MT1-MMP, to promote its endocytosis and recycling
to plasma membrane and therefore to increase cell migration
[4,5], we also studied caveolin-1 immunolocalization. We
observed a colocalization of MT1-MMP and caveolin-1 at the
migration front in Mock cells in accordance with the migratory
phenotype. This aspect disappeared in NC1 a4(IV)-overexpressing
cell, suggesting a loss of the migratory phenotype of the cells [insert
in Figure 4B].
In vivo Tumor Growth is Decreased in Mice Injected with
NC1 a4(IV)-overexpressing Clones
Mock cells or NC1 a4(IV)-overexpressing cells were sub-
cutaneously injected into the left side of athymic nude mice and
tumor volume was measured at days 10, 14, 19 and 26. The clone
expressing the highest level of NC1 a4(IV) was used for this
experiment. Tumor volume at day 26 was decreased by 80% with
NC1 a4(IV)-overexpressing cells comparatively to control Mock
cells (Figure 5A). The same experiment was performed with cells
overexpressing the C-terminal NC1[a4(IV)180-229] domain. No
significant inhibition of tumor growth was observed in this case
(data not shown).
Immunohistochemical staining of tumor sections with an anti
Ki-67 antibody (Figure 5B) showed a decrease in the number of
proliferating cells in tumors developed in mice injected with NC1
a4(IV)-overexpressing cells versus those developed in mice injected
with Mock cells. This result suggests that the effect of the
NC1a4(IV) domain was mediated by its antiproliferative effect
in vivo.
In vitro Effects of the Recombinant NC1 a4(IV)
To rule out a non-specific role of cell transfection in inducing
a putative cell stress, we tested the effect of recombinant NC1
a4(IV) domain on the proliferation and invasion of wild type
UACC-903 melanoma cells.
Recombinant NC1 a4(IV) was expressed in E. coli and purified
or Ni-NTA resin superflow affinity column via its 6 His tag. Its
Figure 7. Recombinant human NC1 a4(IV) binds to avb3 integrin. (A): Adhesion assays were performed as described in the Material and
Methods section. Cells were incubated or not with 5 mM EDTA. Cells were fixed after 30, 60 or 90 min with 1.1% glutaraldehyde and stained with
crystal violet. After elution with 10% acetic acid, absorbance was read at 560 nm. *: p,0.05. Adhesion was restored by the addition of 1.3 mM Ca
2+ or
0.5 mM Mg
2+. (B): Adhesion assays were performed as described in the Material and Methods section. Cells were preincubated for 30 min with an
anti-avb3 blocking antibody or an irrelevant IgG (10 mg/mL) before seeding. Cells were fixed with 1.1% glutaraldehyde and stained with crystal violet.
After elution with 10% acetic acid absorbance was read at 560 nm. *: p,0.05. (C): Surface plasmon resonance (SPR) binding assays were performed
by injecting recombinant human NC1 a4(IV) (3.57 mMa t3 0mL/min) over avb3 integrin immobilized on a CM5 sensor chip (2655 RU). Binding was
expressed as resonance units.
doi:10.1371/journal.pone.0029587.g007
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His and anti-a4(IV) antibodies (Figure 6A).
To assess the effects of recombinant NC1 a4(IV) on cell
proliferation in vitro, wild type UACC-903 cells were incubated
without or with recombinant NC1 a4(IV) domain (10 or 20 mg/
mL). Cell proliferation was inhibited by 45% after a 48 h
incubation period in the presence of 20 mg/mL of recombinant
NC1 a4(IV) (Figure 6B). It also significantly inhibited the
proliferation of the two melanoma cell lines HT-144 and SK-
MEL-28 but not that of normal dermal fibroblasts (Figure 6B). In
all conditions, cell viability was greater than 98% as determined by
trypan blue exclusion.
The recombinant NC1 a4(IV) domain was also tested for its
ability to inhibit tumor cell invasion (Figure 6C). Cell invasion was
inhibited by 44% after a 72 h incubation period. These data
suggest that post-translational modifications did not seem to be
crucial for NC1 a4(IV) biological activity because the effects of the
recombinant protein expressed in E. coli were similar to those
obtained by NC1 a4(IV) overexpression in melanoma cells.
Recombinant NC1 a4(IV) Domain Binds to avb3 Integrin
In order to identify the putative receptor of NC1 a4(IV) domain
on melanoma cells, we studied UACC-903 cell adhesion on
recombinant NC1 a4(IV). UACC-903 cells adhered to the
recombinant NC1 a4(IV). Cell adhesion was inhibited by 5 mM
EDTA and restored in the presence of 1.3 mM Ca
2+ and 0.5 mM
Mg
2+ (Figure 7A). Our previous studies and other studies
demonstrated that NC1 domains of a(IV) collagen chains bind
to cancer cells or endothelial cells through avb3 integrin
[16,17,18,19,20]. Therefore, UACC-903 cells were preincubated
with an anti-avb3 integrin blocking antibody (10 mg/mL). This
significantly inhibited (–38%, p,0.05) cell adhesion on recombi-
nant NC1 a4(IV), whereas preincubation with an irrelevant IgG
had no effect (Figure 7B). To confirm that avb3 is a receptor of
NC1 a4(IV), we performed surface plasmon resonance (SPR)
binding assays (Figure 7C). The NC1 a4(IV) domain bound to the
immobilized avb3 integrin and formed a stable complex that was
dissociated upon addition of 10 mM EDTA, demonstrating that
the binding was dependent upon divalent cations. When the
recombinant NC1 a4(IV) was injected at several concentrations
over avb3 integrin to calculate rate constants and affinity, the
experimental data were best fitted to a two-state model involving
a conformational change in the first complex formed between the
integrin and the NC1 domain leading to the formation of a second,
more stable, complex. The calculated KD=14869.54 nM (n=2)
showed that the NC1 a4(IV) domain bound to the avb3 integrin
with moderate affinity.
Discussion
Although the basement membrane provides a structural support
for epithelial or endothelial cells, recent studies demonstrated that
it also acts as a potential regulator of cell behaviour. During cancer
progression, cross-talk occurs between tumor cells and tumor
micro-environment through cell interactions with basement
membrane macromolecules, mainly with its major constituent,
type IV collagen. This collagen plays a pivotal role in the
regulation of cell proliferation, adhesion and migration either
through the full length molecule, its triple helical domain [27,28]
or through the NC1 domain of its constitutive a(IV) chains [9,29].
For example, systemic administration of recombinant canstatin,
tumstatin or NC1 a6(IV) domain strongly inhibited angiogenesis
and tumor growth in various in vivo cancer models [15]. These
matrikines inhibited endothelial cell proliferation by inducing cell
apoptosis or inhibition of protein synthesis [30,31]. Among these
endogenous angiogenesis inhibitors, canstatin was also shown to
exert anti-tumor properties when overexpressed by cancer cells
[18]. In the same way, we previously demonstrated that tumstatin
inhibited in vitro melanoma cell proliferation and invasion as well
as tumor growth in an experimental murine melanoma model by
down-regulating proteolytic cascades involved in tumor pro-
gression [13]. The anti-tumor activity of tumstatin resided in
a short peptide sequence, CNYYSNS, located within its C-
terminal part [32,33]. The sequence was used as a basis to design
and develop a synthetic cyclopeptide able to exert anti-tumor and
anti-angiogenic activities [34,35].
Up to now, the NC1 a4(IV) domain appeared to be devoid of
anti-angiogenic activity as reported in endothelial cell adhesion
and migration and in chick CAM model [10,15]. Nevertheless,
several synthetic peptides derived from type IV collagen a4 chain,
named tetrastatin-1, -2 and -3 and corresponding to
NC1[a4(IV)54-74], NC1[a4(IV)64-84], NC1[a4(IV)168-187] re-
spectively, have been shown to inhibit human umbilical vein
endothelial cell (HUVEC) proliferation and migration in vitro [36].
In the present study, we demonstrate that the NC1 a4(IV)
domain has anti-tumor effects. Its overexpression by stably
transfected human melanoma cells inhibited their in vitro pro-
liferation without inducing apoptosis. Exogenous recombinant
NC1 a4(IV) domain reproduced the anti-proliferative effect on the
tested melanoma cell lines. This effect seems to be specific to
tumor cells since it was not observed on dermal fibroblasts. The
inhibitory effect induced by exogenously added recombinant NC1
a4(IV) domain rules out a simple induction of cellular stress due to
cell transfection and/or NC1 a4(IV) domain overexpression. The
NC1 a4(IV) domain also strongly decreases in vitro tumor cell
invasion through MatrigelH-coated modified Boyden chambers. In
this model, tumor cell invasion is mainly due to cell adhesion to
MatrigelH and to the proteolytic degradation of MatrigelH by
MMPs and the plasminogen activation system. Overexpression of
the NC1 a4(IV) domain by tumor cells enhances their adhesion to
MatrigelH. However, secretion of MMP-2 and MMP-9 and their
endogenous inhibitors, TIMP-1 and TIMP-2, as well as plasmin
activity were not affected whereas the activation of MT1-MMP
was strongly decreased. Furthermore, the cellular distribution of
MT1-MMP was altered with a loss of MT1-MMP at the migration
front of NC1 a4(IV)-overexpressing cells suggesting a loss of their
migratory phenotype. MT1-MMP is known for degrading various
extracellular matrix macromolecules such as gelatin, elastin,
vitronectin, dermatan sulfate proteoglycans, native fibrillar type
I, II, and III collagens, and laminin-332 [37,38]. The increase in
cell adhesion and the concomitant inhibition of MT1-MMP
activation and cellular distribution could explain the inhibition of
the invasive properties of NC1 a4(IV)-overexpressing cells.
The NC1 a4(IV) domain inhibits in vivo tumor growth in
a mouse xenograft model. The Ki67-immunostaining of tumor
sections shows a decrease in the number of proliferating cells,
contributing to the anti-tumor effect. As we previously demon-
strated for tumstatin, the overexpression of the C-terminal part of
the NC1 a4(IV) domain (NC1 a4(IV) 180-229) also strongly
inhibits in vitro melanoma cell proliferation and their invasive
properties, suggesting that the active sequence of the domain could
be located within this domain. Surprisingly, the C-terminal
fragment of NC1 a4(IV) does not have a significant effect on
tumor growth in the mouse xenograft model. This intriguing result
could be due to a poor secretion of the fragment by transfected
tumor cells, and/or to a higher susceptibility to proteolytic
degradation. Furthermore, the C-terminal fragment used in our
study comprised residues 180-229. Tetrastatin-3, corresponding to
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inhibit HUVEC proliferation and migration [36]. It is possible
that the full in vivo biological activity of the C-terminal fragment of
NC1 a4(IV) requires several extra amino acids present in the
tetrastatin-3 sequence and not in the C-terminal fragment used in
our study. Further investigations to map precisely the bioactive
sequence of NC1 a4(IV) are in progress.
Most collagen IV-derived matrikines act through liganding of
integrins. We previously demonstrated that the anti-tumor C-
terminal fragment of tumstatin binds to melanoma cell avb3
integrin in a RGD-independent manner [16,39]. It was further
confirmed that tumstatin also binds to endothelial cell via avb3
integrin in a RGD-independent manner [40] as well as to avb3
and avb5 integrins via a RGD sequence [20]. Arresten exerts also
its anti-angiogenic effect on endothelial cells by liganding a1b1
integrin [41] and canstatin acts via avb3 and a3b1 integrins [18].
Our results showed that the adhesion of melanoma cells on human
recombinant tetrastatin depended on divalent cations Ca
2+ or
Mg
2+ and was abolished by EDTA and by a blocking anti-avb3
antibody. By surface plasmon resonance binding assays, we found
that tetrastatin binds to avb3 integrin with a moderate affinity
(,148 nM). These results suggest that the avb3 integrin may serve
as a receptor for tetrastatin on melanoma cells although we could
not rule out the possible involvement of other integrin(s) and/or
non-integrin receptor(s) in the anti-tumor activity of tetrastatin.
Further studies are necessary to clarify this point.
A unique nomenclature highlights the new biological functions
of several type IV collagen NC1 domains. We propose that the
NC1 a4(IV) domain be named ‘‘Tetrastatin’’, to highlight the
molecular origin of this matrikine, the a4(IV) collagen chain and
its anti-tumor activity leading to a ‘‘stasis’’ of in vivo tumor growth,
as defined for Hexastatin [18]. Collagen IV-derived matrikines are
promising candidates to develop new anticancer therapeutic
strategies based on specific integrin targeting on both tumor cells
or activated endothelial cells.
Supporting Information
Figure S1 NC1[a4(IV)1-229] overexpression does not
induce UACC-903 cell apoptosis. Cell nuclei were stained
with Hoechst 33342 (1 mg/mL). Nuclear morphology was
visualized with an inverted fluorescence microscope. No nuclear
fragmentation was observed. Scale bar=10 mm.
(TIF)
Figure S2 Effect of NC1 [a4(IV)1-229] overexpression on
proteolytic cascades. Mock or NC1 a4(IV)-overexpressing
cells were incubated for 48 h without FBS. A) Plasmin generated
activity was measured in conditioned media using the H-D-Val-
Leu-Lys-pNA (S-2251) peptide as a substrate and absorbance was
recorded at 405 nm. NS: Non significant, ***: p,0.001. B) MMP
secretion into the conditioned media was analyzed by gelatin
zymography. MMP-2 quantification was performed by densitom-
etry using the Bio-1D software. Results were expressed as arbitrary
units. C) TIMP secretion into the conditioned media was analyzed
by gelatin-plasminogen zymography. TIMP-2 quantification was
performed by densitometry using the Bio-1D software. Results
were expressed as arbitrary units.
(TIF)
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